Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25978080 | 1.00 | ALPL (0.30) | ALPL | |
| SCHEMBL15533714 | 1.00 | ALPL (0.30) | ALPL | |
| SCHEMBL2461024 | 0.76 | — | — | |
| SCHEMBL26257271 | 0.76 | — | — | |
| SCHEMBL23873993 | 0.76 | — | — | |
| SCHEMBL21964688 | 0.76 | — | — | |
| SCHEMBL15817519 | 0.76 | — | — | |
| SCHEMBL765950 | 0.75 | — | — | |
| SCHEMBL12428091 | 0.75 | — | — | |
| SCHEMBL24508262 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-20230038124-A1 | NOVEL SUBSTITUTED CONDENSED RING COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-02-09 | — | — | US | disclosed |
| US-20210147448-A1 | OXO-SUBSTITUTED COMPOUND | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702431-B2 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | ALPL 26/4885 |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | ALPL 527/4885 |
| US-20210147448-A1 | OXO-SUBSTITUTED COMPOUND | CYP51A1, OXA1L, O60361 | ALPL 26/4885 |
| US-20230038124-A1 | NOVEL SUBSTITUTED CONDENSED RING COMPOUND | CYP51A1, HDAC11, MMP9 | ALPL 494/4885 |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | CYP51A1, OXA1L, O60361 | ALPL 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.